Our data provide a mechanistic insight for how SCLC loses MHC-I expression enabling immune cell evasion and strong evidence that combined inhibition of ERBB2 and PD-1 improves outcomes for SCLC patients. This evidence concerns the gene ERBB2 and small cell lung carcinoma.